In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:Current use of regorafenib and TAS-102 monotherapyCombination therapy with regorafenib and PD-1 inhibitorsAdding bevacizumab to TAS-102Presenters:Nilofer S. Azad, MD Professor, Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins UniversityBaltimore, Maryland Kanwal Raghav, MDAssociate Professor, GI Medical Oncology University of Texas MD Anderson Cancer CenterHouston, Texas Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Follow along with the slideset:https://bit.ly/3NLejWeLink to full program:https://bit.ly/33yrIyh

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related